SCHEMBL17784

SCHEMBL17784

CC(C)CNC[C@H]1CN(C(=O)OC(C)(C)C)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ NR1H2 P55055 1/20 0.38
▸ NAMPT P43490 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ PARP1 P09874 2/20 0.37
▸ EPHX2 P34913 1/20 0.37
▸ KAT7 O95251 1/20 0.37
▸ GPR119 Q8TDV5 1/20 0.36
▸ USP2 O75604 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ USP30 Q70CQ3 2/20 0.36
▸ EPHX1 P07099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17184 0.86 ALDH1A1 (0.41) ALDH1A1MAPTNPC1MAPK1HTT
SCHEMBL25214365 0.82 GPR119 (0.38) ALDH1A1MAPTNPC1MAPK1HTT
SCHEMBL17068111 0.81 NR1H2 (0.43) ALDH1A1MAPTNPC1MAPK1HTT
SCHEMBL18342443 0.81 NR1H2 (0.43) ALDH1A1MAPTNPC1MAPK1HTT
SCHEMBL18342442 0.81 NR1H2 (0.43) ALDH1A1MAPTNPC1MAPK1HTT
SCHEMBL4314564 0.80 KDM4E (0.48) ALDH1A1MAPTNPC1MAPK1HTT
SCHEMBL4314752 0.80 KDM4E (0.48) ALDH1A1MAPTNPC1MAPK1HTT
SCHEMBL4838964 0.80 USP2 (0.42) ALDH1A1MAPTNPC1MAPK1HTT
SCHEMBL4835258 0.80 USP2 (0.42) ALDH1A1MAPTNPC1MAPK1HTT
SCHEMBL4835243 0.80 USP2 (0.42) ALDH1A1MAPTNPC1MAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 — — US disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 — — US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 — — US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 ALDH1A1 3293/4885MAPT 3958/4885NPC1 3103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback